Interspecies Brain PBPK Modeling Platform to Predict Passive Transport through the Blood-Brain Barrier and Assess Target Site Disposition.

Authors:
Mehta P; Soliman A; Rodriguez-Vera L; Schmidt S; Muniz P and 4 more

Journal:
Pharmaceutics

Publication Year: 2024

DOI:
10.3390/pharmaceutics16020226

PMCID:
PMC10892872

PMID:
38399280

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pharmaceutics

Abbreviation: Pharmaceutics

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
3D-Printed Alginate/Pectin-Based Patches Loaded with Olive Leaf Extracts for Wound Healing Applicat…
Patitucci F; Motta MF; Dattilo M and 8 more (2024) - Transparency Score: 3/6
3D Printing of Biodegradable Polymeric Microneedles for Transdermal Drug Delivery Applications.
Aldawood FK; Parupelli SK; Andar A and 1 more (2024) - Transparency Score: 3/6
4-(Phenylselanyl)-2H-chromen-2-one-Loaded Nanocapsule Suspension-A Promising Breakthrough in Pain M…
da Fonseca CAR; Prado VC; Paltian JJ and 10 more (2024) - Transparency Score: 4/6
A Bilayer Microarray Patch (MAP) for HIV Pre-Exposure Prophylaxis: The Role of MAP Designs and Form…
Vora LK; Tekko IA; Zanutto FV and 7 more (2024) - Transparency Score: 3/6
Acylation of Oleanolic Acid Oximes Effectively Improves Cytotoxic Activity in In Vitro Studies.
Bednarczyk-Cwynar B; Ruszkowski P. (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest Valvanera Vozmediano, Leyanis Rodriguez-Vera, Monica Rodriguez and Paula Muniz have no conflicts of interest other than being employees of CTI. Marta Forcadell and Emili Gonzalez-Perez have no conflicts of interest other than being employees of Neuraxpharm Pharmaceuticals SL. All the other authors declare no conflicts of interest directly relevant to the content of this manuscript."

Evidence found in paper:

"This research received external funding from Neuraxpharm Pharmaceuticals SL, funding ID: AGR00026961."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025